About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 68337 record(s)
Req # A-2023-000483
A list of every drug approved under Health Canada's Special Access Program (SAP) between January 1, 2018 and July 6, 2023.Organization: Health Canada
January 2024
Req # A-2023-000552
Correspondence relating to any abbreviated new drug submission (ANDS) filed after January 1, 2023 for Estradiol tablets by vaginal route of administration.Organization: Health Canada
January 2024
Req # A-2023-000594
All notes made by the Health Canada employees who reviewed the AstraZeneca Vaxzevria COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: January 1, 2020 to July 31, 2020.Organization: Health Canada
January 2024
Req # A-2023-000601
All notes made by the Health Canada employees who reviewed the Janssen Jcovden (Johnson & Johnson) COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: January 1, 2020 to July 31, 2020.Organization: Health Canada
January 2024
Req # A-2023-000677
Testing records that were submitted to Health Canada as part of a report to the Regulatory Operations and Enforcement Branch regarding the potential presence of prostaglandins in the cosmetic product, Miskoka Beauty Lash and Brow Enhancing Serum (…Organization: Health Canada
January 2024
Req # A-2023-000791
Proposal from Goss Gilroy in response to procurement PR#1000244924.Organization: Health Canada
January 2024
Req # A-2023-000827
Additional details for Natural Health Product (NHP) Site License 300694 (Medline Canada Corporation). If Medline Canada Corporation: is a MANUFACTURER, LABELLER, PACKAGER, or IMPORTER or if it serves as storage/warehouse only. Has listed any FOREIGN…Organization: Health Canada
January 2024
Req # A-2023-000849
All correspondence related to the Estradiol Abbreviated New Drug Submission (ANDS).Organization: Health Canada
January 2024
Req # A-2023-000879
The Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs establishment licence Good Manufacturing Practices (GMP) inspection of the Apotex facility (Site A) on Signet Drive, Toronto,…Organization: Health Canada
January 2024
Req # A-2023-000916
The Abbreviated New Drug Submission (ANDS) no. 262177 filed by JAMP Pharma Corporation for nintedanib or nintedanib esilate, copies of any Notice of Deficiency (NOD), Notice of Non-Compliance (NON), NOD-Withdrawal (NOD-W), or NON-Withdrawal (NON-W…Organization: Health Canada
January 2024